Arrowhead Pharmaceuticals (ARWR) Revenue (2010 - 2026)

Arrowhead Pharmaceuticals (ARWR) has 17 years of Revenue data on file, last reported at $73.7 million in Q1 2026.

• Quarterly Revenue fell 86.41% year-over-year to $73.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $622.0 million (up 14.09% YoY) and the FY2025 annual result came in at $829.4 million, up 23258.15% from the prior year.
• Revenue declined to $73.7 million in Q1 2026, from $264.0 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $542.7 million in Q1 2025 to a low of $2.5 million in Q4 2024.
• A 5-year average of $116.2 million and a median of $47.5 million in 2022 frame the typical range for Revenue.
• Annual changes were most pronounced in 2023 — Revenue tumbled 94.32% — and 2025, when it jumped 10461.32%.
• Tracing ARWR's Revenue over 5 years: stood at $62.5 million in 2022, then plunged by 94.32% to $3.6 million in 2023, then decreased by 29.6% to $2.5 million in 2024, then jumped by 10461.32% to $264.0 million in 2025, then sank by 72.07% to $73.7 million in 2026.
• The last three Revenue figures came in at $73.7 million (Q1 2026), $264.0 million (Q4 2025), and $256.5 million (Q3 2025), per Business Quant data.